Gastrointestinal stromal tumors (GISTs) are driven primarily by oncogenic KIT mutations, and breakthroughs such as imatinib, sunitinib, and ripretinib have transformed the disease’s management. Yet resistance emerges almost universally, driven by secondary KIT mutations—particularly those occurring in the activation loop at exon 17/18, a region historically difficult to inhibit. Patients whose tumors harbor these mutations often progress rapidly, with few effective therapeutic options beyond later-line ripretinib.
The PEAK Phase 3 trial of bezuclastinib, a highly selective, next-generation KIT inhibitor from Cogent Biosciences, addresses this critical unmet need. The company’s announcement of positive topline results positions bezuclastinib as a potentially transformative therapy for patients with KIT activation-loop–mutant GIST.
Read About Gastrointestinal Stromal Tumor on OncoDaily
A Next-Generation KIT Inhibitor Designed for Precision and Selectivity
Bezuclastinib is an orally administered, highly selective KIT inhibitor engineered to target the activation loop—specifically the exon 17/18 mutations that drive resistance to imatinib, sunitinib, regorafenib, and even many newer TKIs. Unlike broad-spectrum inhibitors with multi-kinase off-target effects, bezuclastinib was designed for clean, potent inhibition of KIT with minimal activity against PDGFRα, VEGFR, or other kinases, potentially offering enhanced tolerability and fewer dose-limiting adverse events.
Preclinical evaluations demonstrated strong inhibition of KIT D816V and analogous activation loop mutations, deep suppression of downstream signaling pathways such as MAPK and PI3K/AKT, and robust tumor shrinkage in xenograft models. Clinically, early-phase studies showed promising activity across heavily pretreated GIST populations, supporting advancement into the PEAK Phase 3 trial.
The PEAK Phase 3 Trial: Study Overview
PEAK is a global, randomized Phase 3 trial evaluating bezuclastinib in combination with sunitinib versus sunitinib alone in patients with advanced GIST who have progressed on or are intolerant to imatinib. The trial specifically enrolled patients whose tumors harbor KIT exon 17/18 mutations, reflecting the subgroup most likely to benefit from activation-loop inhibition.
The trial was designed to evaluate whether bezuclastinib could overcome sunitinib resistance by directly targeting the activation loop mutations responsible for disease progression. Progression-free survival, overall response rate, duration of response, and safety formed the primary and secondary outcomes assessed in this study.
Topline Results: A Clinically Meaningful Improvement
According to Cogent Biosciences’ announcement, the PEAK trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for the bezuclastinib combination compared with sunitinib alone. The magnitude of benefit was consistent with the drug’s targeted mechanism, showing pronounced activity in tumors driven by KIT exon 17/18 mutations.
Initial analyses also revealed favorable trends in overall response rate and depth of response. Patients receiving the bezuclastinib combination exhibited higher rates of tumor shrinkage, delayed progression, and more durable responses than those in the control arm. Although full survival data will mature over time, early signals indicate that the addition of bezuclastinib may meaningfully alter the trajectory of resistant GIST.
One notable observation is that bezuclastinib’s benefit occurred without compromising tolerability. Reported adverse events were consistent with expectations for sunitinib, and no new safety signals attributable to bezuclastinib were identified. The drug’s clean selectivity profile may allow prolonged dosing and better adherence, important considerations for the chronic management of GIST.
Why These Results Matter for GIST Treatment
While first-line imatinib continues to provide long-term benefit for many patients, resistance develops through clonal evolution, most commonly involving mutations in KIT exons 13/14 (ATP-binding pocket) or exons 17/18 (activation loop). Sunitinib and regorafenib offer partial control of ATP-pocket mutations, but activation loop mutations remain highly resistant to almost all approved TKIs.
Bezuclastinib directly addresses this resistance mechanism. By selectively targeting the activation loop, it attacks the mutational drivers responsible for disease progression at a molecular level traditional TKIs cannot reach. The positive PEAK results therefore mark one of the most meaningful advancements in the sequential TKI strategy for GIST since ripretinib entered the landscape.
For clinicians, this means the potential for a more precise, biomarker-driven approach: identifying patients with KIT exon 17/18 mutations and offering them therapy specifically designed to neutralize the resistant clone.
Safety Profile and Clinical Considerations
The safety data emerging from the PEAK study align with bezuclastinib’s design principles. The drug appears to maintain a favorable tolerability profile without introducing the broad off-target toxicities often associated with multi-kinase inhibitors. The lack of new safety concerns in combination with sunitinib is encouraging, as combination TKIs can sometimes amplify adverse effects.
The cleaner profile may make bezuclastinib particularly advantageous for patients who experience dose-limiting complications with less selective TKIs, providing an opportunity for sustained treatment exposure necessary for durable disease control.
Implications for Clinical Practice and Future Development
If the PEAK results are supported by full data presentation and regulatory review, bezuclastinib may soon become the preferred treatment option for KIT exon 17/18 mutant GIST after imatinib failure. The drug’s specificity, tolerability, and clear clinical benefit position it to reshape the treatment sequence in a mutation-guided manner.
Beyond PEAK, bezuclastinib is also in development for systemic mastocytosis—another KIT activation loop–driven disease—illustrating the drug’s broad potential across KIT-dependent malignancies. Its success in GIST underscores the value of highly selective inhibitors capable of countering resistance mechanisms that have limited the durability of existing TKIs.
Conclusion
The positive results from the PEAK Phase 3 trial highlight bezuclastinib as a promising and potentially practice-changing therapy for patients with KIT exon 17/18 mutant gastrointestinal stromal tumors. By addressing one of the most formidable resistance mechanisms in GIST biology, bezuclastinib fills a long-standing therapeutic gap and offers clinicians a new pathway toward sustained disease control in a population with limited options.
Pending further analyses and regulatory submissions, bezuclastinib has the potential to become a new standard of care for this genetically defined subset of GIST, bringing precision oncology one step closer to everyday practice.
You Can Watch More on OncoDaily Youtube TV
Written by Armen Gevorgyan, MD